Fig. 1From: Tocilizumab improves survival in severe COVID-19 pneumonia with persistent hypoxia: a retrospective cohort study with follow-up from Mumbai, IndiaSurvival analysis show the effect of tocilizumab on survival. (The median survival in the tocilizumab group was significantly longer than in the control group; 18 days (95% CI: 11.3 to 24.7) versus 9 days (95% CI: 5.7 to 12.3); log rank p 0.007)Back to article page